Deployment
EksoNR at United States
Powered (motor-driven) lower-limb exoskeleton for clinical gait rehabilitation (stroke, spinal-cord injury, acquired brain injury). User intent plus weight-shift triggers powered steps; the device powers the joints, the clinician/patient sets the session. FDA cleared.
EksoNR by Ekso Bionics · Catalog entry · 2 sources · not yet field-verified
Machine-readable surfaces
- Markdown mirror: /deployments/ekso-nr-united-states.md
- JSON-LD: embedded in this page’s head
- REST API: /v1/robots/cbb9eca5-f3b7-4400-a536-a8b6c8b973f6
- Data documentation: /data
- Query this programmatically: Deploy MCP
EksoNR is FDA-cleared for stroke, SCI, acquired brain injury, and multiple sclerosis (first exoskeleton cleared for MS, June 2022). Deployed in 375+ rehabilitation centers worldwide with 200+ published articles. Q1 2026 revenue: Americas $1.55M, EMEA $0.55M, APAC $0.04M. Company disclosed going-concern warning in Q1 2026 10-Q. Pending Business Combination with Applied Digital Cloud (ChronoScale). Go-to-market partners include National Seating & Mobility, Bionic Prosthetics & Orthotics Group, and Ottobock Patient Care.
Key facts
- FDA clearances
- Stroke (2016), SCI T4-L5 and C7-T3 ASIA D, ABI (2020), MS (June 2022, K220988) — first exoskeleton cleared for MS rehab
- Clinical scale
- 375+ rehabilitation centers worldwide; 200+ published articles; 2,000+ patients across 185+ clinical studies
- Americas revenue Q1 2026
- $1.55M (US $1.53M)
- Going concern
- Q1 2026 10-Q discloses substantial doubt; cash funds operations into early Q3 2026; Business Combination with Applied Digital Cloud pending
- Go-to-market partners
- National Seating & Mobility, Bionic Prosthetics & Orthotics Group, Ottobock Patient Care
- Trust tier
- Catalog entry · 2 sources · not yet field-verified
- Last updated
- 2026-06-07
- Model
- EksoNR
- Company
- Ekso Bionics
- Location
- United States
- Status
- active
- ID
cbb9eca5-f3b7-4400-a536-a8b6c8b973f6
Sources (2)
Methodology: Verified · 2 sources (1 primary) · last reviewed 2026-06-07
Verification posture
Verified
High confidence
Review state
Stable
Last reviewed 2026-06-07
Maturity + lifecycle
Maturity stage: commercial
Lifecycle: active
Architectural position
Cohort: exoskeleton
Sources by quality tier
- 1
- unclassified
- Unclassified source
- 1
- primary-company-ir
- Company IR disclosure
The framework is documented at /methodology. Corrections at /corrections. Reviewer: DEPLOY editorial team.
Methodology surface for EksoNR at United States.Common questions
- What is the EksoNR deployment at United States?
- EksoNR, built by Ekso Bionics, is recorded as a deployment at United States on the DEPLOY registry. Ekso Bionics operates the deployment directly.
- Who operates EksoNR at United States?
- Ekso Bionics, the manufacturer of EksoNR, operates this deployment directly. This is a maker-deploys-its-own-product arrangement rather than a customer pilot.
- Is the EksoNR deployment at United States still active?
- As of the most recent verification on the DEPLOY registry, this deployment is currently operating.
- Have there been incidents at the EksoNR deployment at United States?
- No active incidents affecting this deployment are recorded on the DEPLOY registry. Absence of recorded incidents is not a guarantee no incident occurred; DEPLOY records only sourced incidents and suppresses retracted ones.
Deploy Watch
Track this deployment.
We notify you when status changes against primary-source evidence, contract events surface, or a related incident is filed.